{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"13"}],"units":"Participants"}],"groups":[{"description":"Denileukin diftitox was intravenously (IV) infused for 60 minutes (±10 minutes) daily from Day 1 through Day 5 of each Cycle (1 cycle = 3 weeks).","id":"BG000","title":"Cohort 1: 6 ug/kg/Day Denileukin Diftitox"},{"description":"Denileukin diftitox was IV-infused for 60 minutes (±10 minutes) daily from Day 1 through Day 5 of each Cycle (1 cycle = 3 weeks).","id":"BG001","title":"Cohort 2: 9 ug/kg/Day Denileukin Diftitox"},{"description":"Denileukin diftitox was IV-infused for 60 minutes (±10 minutes) daily from Day 1 through Day 5 of each Cycle (1 cycle = 3 weeks).","id":"BG002","title":"Cohort 3: 12 ug/kg/Day Denileukin Diftitox"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"5.51","value":"69.7"},{"groupId":"BG001","spread":"17.74","value":"49.9"},{"groupId":"BG002","spread":"4.16","value":"66.3"},{"groupId":"BG003","spread":"15.98","value":"58.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"8"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Safety analysis set included all participants who received at least one dose of the study drug with at least one evaluable, post-baseline safety datum."}